The immunology of psoriasis and biologic immunotherapy.

[1]  D. West,et al.  Biologic therapy for psoriasis: the new therapeutic frontier. , 2002, Archives of dermatology.

[2]  P. Bongrand,et al.  Intercellular transfer of antigen‐presenting cell determinants onto T cells: molecular mechanisms and biological significance , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[3]  M. Aringer.  T lymphocyte activation--an inside overview. , 2002, Acta medica Austriaca.

[4]  G. Krueger,et al.  Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. , 2001, The New England journal of medicine.

[5]  P. Friedl,et al.  Interaction of T cells with APCs: the serial encounter model. , 2001, Trends in immunology.

[6]  James G Krueger,et al.  Potential Role of the Chemokine Receptors CXCR3, CCR4, and the Integrin αEβ7 in the Pathogenesis of Psoriasis Vulgaris , 2001, Laboratory Investigation.

[7]  B. Nickoloff,et al.  Keratinocyte CDw60 expression is modulated by both a Th-1 type cytokine IFN-gamma and Th-2 cytokines IL-4 and IL-13: relevance to psoriasis. , 2001, The Journal of investigative dermatology.

[8]  B. Nickoloff,et al.  Characterization of lymphocyte-dependent angiogenesis using a SCID mouse: human skin model of psoriasis. , 2000, The journal of investigative dermatology. Symposium proceedings.

[9]  C. Caux,et al.  Up-Regulation of Macrophage Inflammatory Protein-3α/CCL20 and CC Chemokine Receptor 6 in Psoriasis1 , 2000, The Journal of Immunology.

[10]  M. Lebwohl,et al.  Effects of administration of a single dose of a humanized monoclonal antibody to CD11a on the immunobiology and clinical activity of psoriasis. , 2000, Journal of the American Academy of Dermatology.

[11]  T. Kupper,et al.  Inflammatory skin diseases, T cells, and immune surveillance. , 1999, The New England journal of medicine.

[12]  J. Koo.  Current Consensus and Update on Psoriasis Therapy: A Perspective from the U.S. , 1999, The Journal of dermatology.

[13]  M. Müller,et al.  Combined analysis of polymorphisms of the tumor necrosis factor-alpha and interleukin-10 promoter regions and polymorphic xenobiotic metabolizing enzymes in psoriasis. , 1999, The Journal of investigative dermatology.

[14]  Franco Ameglio,et al.  Cytokines in psoriasis , 1999, International journal of dermatology.

[15]  G. Tydén,et al.  Zenapax (daclizumab) reduces the incidence of acute rejection episodes and improves patient survival following renal transplantation. No 14874 and No 14393 Zenapax Study Groups. , 1999, Transplantation proceedings.

[16]  N. Yawalkar,et al.  Expression of interleukin-12 is increased in psoriatic skin. , 1998, The Journal of investigative dermatology.

[17]  H. Moon,et al.  Psoriasiform eruption triggered by recombinant granulocyte-macrophage colony stimulating factor (rGM-CSF) and exacerbated by granulocyte colony stimulating factor (rG-CSF) in a patient with breast cancer. , 1998, Journal of Korean medical science.

[18]  Y. Ueyama,et al.  Histological and immunocytochemical studies of human psoriatic lesions transplanted onto SCID mice. , 1998, Journal of dermatological science.

[19]  M. Holick,et al.  Administration of DAB389IL-2 to patients with recalcitrant psoriasis: a double-blind, phase II multicenter trial. , 1998, Journal of the American Academy of Dermatology.

[20]  K. Nishioka,et al.  Repeated subcutaneous injection of staphylococcal enterotoxin B-stimulated lymphocytes retains epidermal thickness of psoriatic skin-graft onto severe combined immunodeficient mice. , 1998, Journal of dermatological science.

[21]  W Sterry,et al.  IL-10 is a key cytokine in psoriasis. Proof of principle by IL-10 therapy: a new therapeutic approach. , 1998, The Journal of clinical investigation.

[22]  Sato,et al.  RANTES expression in psoriatic skin, and regulation of RANTES and IL‐8 production in cultured epidermal keratinocytes by active vitamin D3 (tacalcitol) , 1998, The British journal of dermatology.

[23]  J. Kieffer,et al.  Cutaneous lymphocyte antigen is a specialized form of PSGL-1 expressed on skin-homing T cells , 1997, Nature.

[24]  Y. Ullmann,et al.  T-lymphocyte dependence of psoriatic pathology in human psoriatic skin grafted to SCID mice. , 1997, The Journal of investigative dermatology.

[25]  L. Adorini,et al.  Immune deviation towards Th2 inhibits Th-1-mediated autoimmune diabetes. , 1997, Biochemical Society transactions.

[26]  E. Bröcker,et al.  Differential Expression of GRO-α and IL-8 mRNA Psoriasis: A Model for Neutrophil Migration and Accumulation In Vivo , 1996 .

[27]  B. Nickoloff,et al.  Dermal injection of immunocytes induces psoriasis. , 1996, The Journal of clinical investigation.

[28]  T. Zollner,et al.  Pulling the trigger on psoriasis , 1996, Nature.

[29]  F. Finkelman.  Relationships among antigen presentation, cytokines, immune deviation, and autoimmune disease , 1995, The Journal of experimental medicine.

[30]  James G. Krueger,et al.  Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis , 1995, Nature Genetics.

[31]  M. Burdick,et al.  Severe combined immunodeficiency mouse and human psoriatic skin chimeras. Validation of a new animal model. , 1995, The American journal of pathology.

[32]  D. Wallach,et al.  Elevated tumour necrosis factor‐alpha (TNF‐α) biological activity in psoriatic skin lesions , 1994, Clinical and experimental immunology.

[33]  W. Jochum,et al.  T cells involved in psoriasis vulgaris belong to the Th1 subset. , 1994, The Journal of investigative dermatology.

[34]  J. Trowsdale,et al.  COMPLEXITY IN THE MAJOR HISTOCOMPATIBILITY COMPLEX , 1992, European journal of immunogenetics : official journal of the British Society for Histocompatibility and Immunogenetics.

[35]  T. Strom,et al.  DAB486IL‐2 (IL‐2 Toxin) Selectively Inactivates High‐Affinity IL‐2 Receptor‐Bearing Human Peripheral Blood Mononuclear Cells , 1991, Annals of the New York Academy of Sciences.

[36]  L. Picker,et al.  ELAM-1 is an adhesion molecule for skin-homing T cells , 1991, Nature.

[37]  J. Billings,et al.  Cyclosporine improves psoriasis in a double-blind study. , 1986, JAMA.

[38]  J. Bos,et al.  Immunocompetent cells in psoriasis , 1983, Archives of Dermatological Research.

[39]  W. Mueller,et al.  Cyclosporin A for psoriasis. , 1979, The New England journal of medicine.

[40]  R. Matre,et al.  Characterization of mononuclear cell infiltrates in psoriatic lesions. , 1978, The Journal of investigative dermatology.

[41]  C. Pert,et al.  Upregulation of RANTES in psoriatic keratinocytes: a possible pathogenic mechanism for psoriasis. , 1999, Acta dermato-venereologica.

[42]  M. Sekimata,et al.  Different growth properties in response to epidermal growth factor and interleukin-6 of primary keratinocytes derived from normal and psoriatic lesional skin. , 1998, Journal of dermatological science.

[43]  M. Berridge.  Lymphocyte activation in health and disease. , 1997, Critical reviews in immunology.

[44]  E. Parra,et al.  T cell activation pathways: B7, LFA-3, and ICAM-1 shape unique T cell profiles. , 1995, Critical reviews in immunology.

[45]  B. Julian,et al.  OKT3 first-dose reaction: association with T cell subsets and cytokine release. , 1991, Kidney international.